

Personalised Stratified Follow Up (PSFU)

Andrea Webber, Personalised Care Manager

What is PSFU?

At the end of treatment if a patient is suitable for PSFU they will continue to undergo routine tests where applicable but will not have regular face-to-face appointments with a nurse or consultant.

They follow a clinical protocol agreed by Pathway Board. Patients follow the same protocol across Greater Manchester allowing for standardisation of follow up.

Benefits to patients

- Patients will manage their own health resulting in better outcomes
- Rapid access back to their medical team when needed
- No travelling to appointments when well, saving time and money
- Get test results quicker
- Allows resource to be reallocated so complex patients can be seen more quickly

Digital Remote Monitoring System (Infoflex) allows patients to be safely and efficiently tracked.

Data (demographic, cancer, path, rad, endo) data feeds in from every Trust in Greater Manchester.



All patients on a stratified follow up pathway will be in Infoflex (including those on EPIC). Allows for sharing of information across GM.

Which tumour groups stratify patients?

Currently

Breast, Prostate
Colorectal, Endometrial

Plans to roll out to

Cervical, Ovarian, Bladder, Renal, Pancreatic, Lung, Thyroid, CLL with discussions with other pathway boards ongoing

Current numbers of patients on a stratified pathway

- 1800 individual patients in Infoflex (added in last 8 months and a rollout of training to all Trusts underway so numbers will rise significantly)
- 1000 prostate patients on PSFU at The Christie to be transferred into the system
- 4500 reviews already undertaken or planned
- 1500 + individual patients tracked on Epic (MFT)

- Projected to be tracking up to 7000 patients on Infoflex by the end of March 2025, allowing a projected 2500 + clinic slots to be repurposed
- A full evaluation of the service will be published later this year